NEXALIS THERAPEUTICS LTD — Director's Dealing 2021

Jul 25, 2021

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Lifespot Health Limited
ABN	90 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director Justyn Stedwell

Date of last notice 13 November 2020

Date that director ceased to be director 20 July 2021

Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

• See chapter 19 for defined terms.

Appendix 3Z Page 1

11/3/2002

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances givingrise to the relevant interestNil	Number & class of securitiesN/A

Part 3 – Director’s interests in contracts

Detail of contract	Agreement to issue Options
Nature of interest	Direct
Name of registered holder(if issued securities)	Justyn Stedwell or his nominee
No. and class of securities to whichinterest relates	Agreement to be Issued 1,000,000 Optionssubject to shareholder approval.

• See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002